275 related articles for article (PubMed ID: 35408919)
1. Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?
Turinetto M; Valsecchi AA; Tuninetti V; Scotto G; Borella F; Valabrega G
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408919
[TBL] [Abstract][Full Text] [Related]
2. Recurrent or primary metastatic cervical cancer: current and future treatments.
Gennigens C; Jerusalem G; Lapaille L; De Cuypere M; Streel S; Kridelka F; Ray-Coquard I
ESMO Open; 2022 Oct; 7(5):100579. PubMed ID: 36108558
[TBL] [Abstract][Full Text] [Related]
3. Tisotumab vedotin for the treatment of cervical carcinoma.
Song X; Li R; Wang H; Song P; Guo W; Chen ZS
Drugs Today (Barc); 2022 May; 58(5):213-222. PubMed ID: 35535813
[TBL] [Abstract][Full Text] [Related]
4. Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?
Vergote I; Ray-Coquard I; Lorusso D; Oaknin A; Cibula D; Van Gorp T
Expert Opin Investig Drugs; 2023 Mar; 32(3):201-211. PubMed ID: 36803278
[TBL] [Abstract][Full Text] [Related]
5. The abscopal effect of immune-radiation therapy in recurrent and metastatic cervical cancer: a narrative review.
Ollivier L; Moreau Bachelard C; Renaud E; Dhamelincourt E; Lucia F
Front Immunol; 2023; 14():1201675. PubMed ID: 37539054
[TBL] [Abstract][Full Text] [Related]
6. Top advances of the year: Cervical cancer.
Podwika SE; Duska LR
Cancer; 2023 Mar; 129(5):657-663. PubMed ID: 36609769
[TBL] [Abstract][Full Text] [Related]
7. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels JP; Arkenau HT; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Sørensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U
Lancet Oncol; 2019 Mar; 20(3):383-393. PubMed ID: 30745090
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Coleman RL; Lorusso D; Gennigens C; González-Martín A; Randall L; Cibula D; Lund B; Woelber L; Pignata S; Forget F; Redondo A; Vindeløv SD; Chen M; Harris JR; Smith M; Nicacio LV; Teng MSL; Laenen A; Rangwala R; Manso L; Mirza M; Monk BJ; Vergote I;
Lancet Oncol; 2021 May; 22(5):609-619. PubMed ID: 33845034
[TBL] [Abstract][Full Text] [Related]
9. A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin.
Luu K; Chu A; Chang B
J Oncol Pharm Pract; 2023 Mar; 29(2):441-449. PubMed ID: 36415085
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in Cervical Cancer.
Mauricio D; Zeybek B; Tymon-Rosario J; Harold J; Santin AD
Curr Oncol Rep; 2021 Apr; 23(6):61. PubMed ID: 33852056
[TBL] [Abstract][Full Text] [Related]
11. A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer.
Heitz N; Greer SC; Halford Z
Ann Pharmacother; 2023 May; 57(5):585-596. PubMed ID: 35962528
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in cervix cancer.
Attademo L; Tuninetti V; Pisano C; Cecere SC; Di Napoli M; Tambaro R; Valabrega G; Musacchio L; Setola SV; Piccirillo P; Califano D; Spina A; Losito S; Greggi S; Pignata S
Cancer Treat Rev; 2020 Nov; 90():102088. PubMed ID: 32827839
[TBL] [Abstract][Full Text] [Related]
13. Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer.
Mutlu L; Tymon-Rosario J; Harold J; Menderes G
Expert Rev Anticancer Ther; 2022 Jun; 22(6):633-645. PubMed ID: 35533682
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer.
Huang H; Nie CP; Liu XF; Song B; Yue JH; Xu JX; He J; Li K; Feng YL; Wan T; Zheng M; Zhang YN; Ye WJ; Li JD; Li YF; Li JY; Cao XP; Liu ZM; Zhang XS; Liu Q; Zhang X; Liu JH; Li J
J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35727633
[TBL] [Abstract][Full Text] [Related]
15. Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.
Dyer BA; Zamarin D; Eskandar RN; Mayadev JM
J Natl Compr Canc Netw; 2019 Jan; 17(1):91-97. PubMed ID: 30659133
[TBL] [Abstract][Full Text] [Related]
16. Mitigation and management strategies for ocular events associated with tisotumab vedotin.
Kim SK; Ursell P; Coleman RL; Monk BJ; Vergote I
Gynecol Oncol; 2022 May; 165(2):385-392. PubMed ID: 35277279
[TBL] [Abstract][Full Text] [Related]
17. Tisotumab vedotin in recurrent or metastatic cervical cancer.
Bogani G; Coleman RL; Vergote I; Raspagliesi F; Lorusso D; Monk BJ
Curr Probl Cancer; 2023 Jun; 47(3):100952. PubMed ID: 36842202
[TBL] [Abstract][Full Text] [Related]
18. Current Status of Clinical Trials for Cervical and Uterine Cancer Using Immunotherapy Combined With Radiation.
Dyer BA; Feng CH; Eskander R; Sharabi AB; Mell LK; McHale M; Mayadev JS
Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):396-412. PubMed ID: 32942005
[TBL] [Abstract][Full Text] [Related]
19. Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives.
Giudice E; Mirza MR; Lorusso D
Curr Oncol Rep; 2023 Nov; 25(11):1307-1326. PubMed ID: 37870697
[TBL] [Abstract][Full Text] [Related]
20. The Role of Biomarkers for the Prediction of Response to Checkpoint Immunotherapy and the Rationale for the Use of Checkpoint Immunotherapy in Cervical Cancer.
Otter SJ; Chatterjee J; Stewart AJ; Michael A
Clin Oncol (R Coll Radiol); 2019 Dec; 31(12):834-843. PubMed ID: 31331818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
